Burgess SV, Hussaini T, Yoshida EM

Idioma: Ingles.
Referencias bibliográficas: 22
Paginas: 154-159
Archivo PDF: 137.55 Kb.

RESUMEN

Sin resumen.

REFERENCIAS (EN ESTE ARTÍCULO)

1. MohdHanafiah K, Groeger J, Flaxman AD, Wiersma ST. Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence. Hepatology 2013; 57: 1333-42.

2. Lozano R, Naghavi M, Foreman K, Lim S, Shibuya K, Aboyans V, Abraham J, et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: A systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012; 380: 2095-128.

3. Diagnosis, management, and treatment of hepatitis C: An update. AASLD Practice Guidelines.Hepatology 2009; 49: 1335-74.

4. US Food and Drug Administration Guidance for Industry Chronic Hepatitis C Virus Infection: Developing Direct- Acting Antiviral Drugs for Treatment 2013; October. Available at http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/ guidances/ucm225333.pdf

5. Van der Meer A, Veldt B, Feld J, Wedemeyer H, Dufour J. Association between sustained virological response and allcause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis. JAMA 2012; 308: 2584-93.

6. Pearlman BL, Traub N. Sustained virologic response to antiviral therapy for chronic hepatitis C virus infection: A cure and so much more. Clin Infect Dis 2011; 52: 889-900.

7. Maylin S, Martinot-Peignoux M, Ripault M-P, Moucari R, Cardoso AC, Boyer N, Giuily N, et al. Sustained virological response is associated with clearance of hepatitis C virus RNA and a decrease in hepatitis C virus antibody. Liver Int 2009; 29: 511-7.

8. Swain MG, Lai M, Shiffman ML, Cooksley WGE, Zeuzem S, Dieterich DT, Abergel A, et al. A sustained virologic response is durable in patients with chronic hepatitis C treated with peginterferon Alfa-2a and ribavirin. Gastroenterology 2010; 139: 1593-601.

9. Martinot-Peignoux M, Stern C, Maylin S, Ripault MP, Boyer N, Leclere L, Castelneu C, et al. Twelve weeks posttreatment follow-up is as relevant as 24 weeks to determine the sustained virologic response in patients with hepatitis c virus receiving pegylated interferon and ribavirin. Hepatology 2010; 51: 1122-6.

10. Chen J, Florian J, Carter W, Fleischer RD, Hammerstrom TS, Jadhav PR, Zeng W, et al. Earlier sustained virologic response end points for regulatory approval and dose selection of hepatitis C therapies. Gastroenterology 2013; 144: 1450-5.e2.

11. Zeuzem S, Heathcote EJ, Shiffman ML, Wright TL, Bain VG, Sherman M, Feinman V, et al. Twelve weeks of follow-up is sufficient for the determination of sustained virologic response in patients treated with interferon α for chronic hepatitis C. J Hepatol 2003; 39: 106-11.

12. AASLD/IDSA/IAS-USA. Recommendations for testing, managing, and treating hepatitis C. Available from: http:// www.hcvguidelines.org[cited 2015, Sep 1].

13. Manns MP, von Hahn T. Novel therapies for hepatitis C - one pill fits all? Nat Rev Drug Discov Nature Publishing Group 2013; 12: 595-610.

14. Poordad F, Agarwal K, Younes Z, Cohen D, Xie W, Podsadecki T. Low relapse rate leads to high concordance of sustained virologic response (SVR) at 12 weeks with SVR at 24 weeks after treatment with ABT-450/ritonavir, ombitasvir, and dasabuvir plus ribavirin in subjects with chronic hepatitis C virus genotype 1 infect. Clin Infect Dis 2014; 60: 608-10.

15. Kowdley KV, Lawitz E, Poordad F, Cohen DE, Nelson DR, Zeuzem S, Everson GT, et al. Phase 2b trial of interferonfree therapy for hepatitis C virus genotype 1. N Engl J Med2014; 370: 222-32.

16. Yoshida EM, Sulkowski MS, Gane EJ, Herring RW, Ratziu V, Ding X, Wang J, et al. Concordance of sustained virological response 4, 12, and 24 weeks post-treatment with sofosbuvir- containing regimens for hepatitis C virus.Hepatology 2015; 61: 41-5.

17. Bernstein D, Mangia A, Brau N, Yang J, Ma J, Hyland R, Pang P, et al. Concordance between SVR4, SVR12 and SVR24 in genotype 1 HCV-infected patients who received all oral fixed-dose combination ledipasvir/sofosbuvir with or without ribavirin in phase 3 clinical trials [Abstract 1947] 2014 AASLD Conference. Hepatology 2014; 1142-3.

18. Lawitz E, Gane EJ, Lalezari J, Hyland RH, Ma J, Symonds WT, Hassanein T, et al. High concordance of SVR4, SVR12, and SVR24 in patients with HCV infection who have received treatment with sofosbuvir [Abstract 848]. J Hepatol 2013; 58: S348.

19. Lawitz E, Hezode C, Varunok P, Thuluvath P, Baykal T, Kapoor M, Lovell S, et al. Concordance of SVR12 with SVR4 and SVR24 in patients with chronic HCV genotype 1b treated with the interferon- and ribavirin-free ABT-450/r and ABT-267 regimen. [Abstract] 23rd Conference of the Asian Pacific Association for the Study of the Liver; March 12-15, 2014.

20. Lawitz W, Hezode C, Varunok P, Thuluvath P, Baykal T, Kapoor M, Lovell S, et al. Interferon-and ribavirin-free regimen of ABT-450/r + ABT-267 in HCV genotype 1b-infected treatment- naïve patients and prior null responders: PEARL-I. [Abstract] 64th Annual Meeting of the American Association for the Study of Liver Diseases; November 1-5, 2013.

21. Zeuzem S, Soriano V, Asselah T, Bronowicki J, Lohse A, Mullhaupt B, Schuchmann M, et al. SOUND-C2: SVR4, 12, and 24 concordance in genotype (GT) 1 HCV patients receiving interferon (IFN)-free treatment with the HCV NS3/4A protease inhibitor BI 201335 and the NS5B polymerase inhibitor BI 207127. [Abstract] 63rd Annual Meeting of the American Association for the Study of Liver Diseases. Hepatology 2012; 569A.

22. Cheng W, Shafran S, Beavers K, Mo H, McNally J, Brainard D, et al. Long term follow-up of patients treated with sofosbuvir in the FISSION, POSITRON, FUSION and NEUTRINO phase 3 studies. 49th Annual Meeting of the European Association for the Study of the Liver, International Liver Congress 2014 London United Kingdom. J Hepatol 2014; S449.